HighVista Strategies sold 238,243 shares of Viridian Therapeutics; the estimated trade size was $7.08 million based on average closing prices from January through March 2026.
The quarter-end position value decreased by $8.97 million, reflecting both the share sale and stock price changes during the period.
The move represents a 1.95% change in HighVista’s 13F reportable assets under management.
Post-trade, HighVista holds 134,229 shares valued at $2.63 million.
HighVista Strategies reported a sale of 238,243 shares of Viridian Therapeutics (NASDAQ:VRDN) in its May 15, 2026, SEC filing, an estimated $7.08 million trade based on quarterly average pricing.
According to a SEC filing dated May 15, 2026, HighVista Strategies reduced its stake in Viridian Therapeutics (NASDAQ:VRDN) by 238,243 shares during the first quarter. The estimated value of shares sold was about $7.08 million, based on the period’s average closing price. After accounting for stock price movements, the quarter-end value of the position declined by $8.97 million.
| Metric | Value |
|---|---|
| Revenue (TTM) | $70.85 million |
| Net Income (TTM) | ($342.6 million) |
| Price (as of market close 2026-05-14) | $17.43 |
| One-Year Price Change | 35% |
Viridian Therapeutics is a clinical-stage biotechnology company specializing in the development of antibody-based therapies for serious diseases, with an emphasis on thyroid eye disease. The company leverages advanced monoclonal antibody technology to address unmet medical needs in its target markets. Its strategic focus on innovative biologics positions it to compete in the evolving landscape of specialty therapeutics.
Viridian has climbed roughly 35% over the past year, and with a June 30 FDA decision looming for lead therapy veligrotug, some investors may be locking in gains. The company also faced some pressure right at the end of last quarter, with shares falling over 30% after the firm reported Phase 3 TED data that was positive, but fell short of expectations.
Still, the broader business momentum continues to look solid. Earlier this month, Viridian said it is “launch-ready” ahead of veligrotug’s PDUFA date and highlighted positive Phase 3 data for subcutaneous candidate elegrobart in both active and chronic thyroid eye disease. Management believes elegrobart could become the first subcutaneous autoinjector treatment for TED, potentially giving the company a differentiated commercial angle in a market currently dominated by infusions.
For long-term investors, the story now increasingly hinges on execution. A successful FDA approval and launch could materially reshape Viridian’s profile from a development-stage biotech into a commercial rare disease player.
Before you buy stock in Viridian Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Viridian Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $469,293!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $1,381,332!*
Now, it’s worth noting Stock Advisor’s total average return is 993% — a market-crushing outperformance compared to 207% for the S&P 500. Don’t miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of May 17, 2026.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
—
Blog powered by G6
Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.
For any inquiries, please contact [email protected]
